BR112016003293A8 - Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos - Google Patents
Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicosInfo
- Publication number
- BR112016003293A8 BR112016003293A8 BR112016003293A BR112016003293A BR112016003293A8 BR 112016003293 A8 BR112016003293 A8 BR 112016003293A8 BR 112016003293 A BR112016003293 A BR 112016003293A BR 112016003293 A BR112016003293 A BR 112016003293A BR 112016003293 A8 BR112016003293 A8 BR 112016003293A8
- Authority
- BR
- Brazil
- Prior art keywords
- rheumatoid arthritis
- neutralizing antibodies
- csf neutralizing
- treatment
- analgesics
- Prior art date
Links
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title abstract 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title abstract 4
- 230000003472 neutralizing effect Effects 0.000 title abstract 4
- 206010039073 rheumatoid arthritis Diseases 0.000 title abstract 3
- 229940035676 analgesics Drugs 0.000 title 1
- 239000000730 antalgic agent Substances 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
ANTICORPO NEUTRALIZANTE DE GM-CSF, SEU USO, COMPOSIÇÃO FARMACÊUTICA E KIT A presente invenção refere-se a anticorpos neutralizantes de GM-CSF e composições compreendendo os mesmos para uso no tratamento de desordens inflamatórias, tais como artrite reumatoide de acordo com regime de dosagem específico. A invenção refere-se também a anticorpos neutralizantes de GM-CSF e composições compreendendo os mesmos para uso no tratamento da dor, por exemplo, dor experimentada nas desordens inflamatórias, tais como artrite reumatoide, de acordo com o regime de dosagem específica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361871904P | 2013-08-30 | 2013-08-30 | |
| US201361871900P | 2013-08-30 | 2013-08-30 | |
| PCT/EP2014/068489 WO2015028657A1 (en) | 2013-08-30 | 2014-09-01 | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016003293A2 BR112016003293A2 (pt) | 2017-11-21 |
| BR112016003293A8 true BR112016003293A8 (pt) | 2022-08-16 |
Family
ID=51454704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016003293A BR112016003293A8 (pt) | 2013-08-30 | 2014-09-01 | Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10745475B2 (pt) |
| EP (2) | EP3039039B1 (pt) |
| JP (4) | JP2016536327A (pt) |
| KR (3) | KR20220045064A (pt) |
| CN (2) | CN118178647A (pt) |
| AU (3) | AU2014314053C1 (pt) |
| BR (1) | BR112016003293A8 (pt) |
| CA (1) | CA2922251C (pt) |
| ES (1) | ES2860480T3 (pt) |
| MX (2) | MX2016002177A (pt) |
| RU (1) | RU2714919C2 (pt) |
| WO (1) | WO2015028657A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004241101B2 (en) | 2003-05-15 | 2010-05-13 | Ampio Pharmaceuticals, Inc. | Treatment of T-cell mediated diseases |
| MY167804A (en) | 2011-10-10 | 2018-09-26 | Ampio Pharmaceuticals Inc | Treatment of degenerative joint disease |
| EP4066836A1 (en) | 2014-08-18 | 2022-10-05 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
| US11389512B2 (en) | 2015-06-22 | 2022-07-19 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
| MX2019003019A (es) | 2016-09-19 | 2019-09-19 | I Mab | Anticuerpos anti-gm-csf y usos de los mismos. |
| CN107840885B (zh) * | 2016-09-19 | 2020-11-10 | 天境生物科技(上海)有限公司 | Gm-csf抗体及其用途 |
| EP3576790A4 (en) | 2017-02-01 | 2020-12-23 | Yale University | TREATMENT OF DIURETIC RESISTANCE |
| PE20211196A1 (es) * | 2018-01-05 | 2021-07-01 | Novo Nordisk As | Metodos para tratar inflamacion mediada por il-6 sin inmunosupresion |
| WO2019178379A2 (en) * | 2018-03-14 | 2019-09-19 | Indiana University Research And Technology Corporation | Precision medicine for pain: diagnostic biomarkers, pharmacogenomics, and repurposed drugs |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2916711A1 (de) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
| US4783441A (en) | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
| JPS59147297A (ja) | 1983-02-10 | 1984-08-23 | 株式会社日立製作所 | 原子炉圧力容器の耐震構造 |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3583880D1 (de) | 1984-04-09 | 1991-10-02 | Takeda Chemical Industries Ltd | Stabile interleukin-2-zusammensetzung. |
| GB8624899D0 (en) | 1986-10-17 | 1986-11-19 | Sandoz Ltd | Monoclonal antibodies |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5070013A (en) | 1988-05-31 | 1991-12-03 | Schering Corporation | Immunochemical assay for human granulocyte-macrophage colony stimulating factor |
| GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
| WO1994009149A1 (en) | 1990-08-10 | 1994-04-28 | Amrad Corporation Limited | Monoclonal antibody |
| CA2060741A1 (en) | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Gm-csf inhibiting oligopeptides |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| US6309636B1 (en) | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| EP2275119B1 (en) | 1995-07-27 | 2013-09-25 | Genentech, Inc. | Stable isotonic lyophilized protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| NZ507381A (en) | 1998-04-21 | 2003-12-19 | Micromet Ag | CD19xCD3 specific polypeptides and uses thereof |
| CN100391469C (zh) | 2000-02-14 | 2008-06-04 | 三菱制药株式会社 | 丙型肝炎治疗药 |
| US20050271663A1 (en) | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| MXPA04000747A (es) | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
| IL161677A0 (en) | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| ATE509032T1 (de) | 2002-02-13 | 2011-05-15 | Ludwig Inst For Cancer Res Ltd | Chimerizierte gm-csf antikörper |
| ES2311094T3 (es) | 2002-02-27 | 2009-02-01 | Immunex Corporation | Composicion estabilizada de tnfr-fc que comprende arginina. |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| EP1576011B1 (en) | 2002-10-30 | 2009-08-12 | Genentech, Inc. | Inhibition of il-17 production |
| AU2005249360B2 (en) | 2004-04-12 | 2011-07-21 | Medimmune, Llc | Anti-IL-9 antibody formulations and uses thereof |
| ATE435238T1 (de) | 2004-05-05 | 2009-07-15 | Micromet Ag | Herstellung eines einkettigen fv antikörperfragments |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2006066088A2 (en) | 2004-12-16 | 2006-06-22 | Genentech, Inc. | Methods for treating autoimmune disorders |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| EA013162B1 (ru) | 2005-04-18 | 2010-02-26 | Микромет Аг | Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека |
| PT3620171T (pt) | 2005-05-18 | 2022-06-30 | Morphosys Ag | Anticorpos anti-gm-csf e suas utilizações |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| CA2638811A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| HUE032584T2 (en) | 2006-02-08 | 2017-09-28 | Morphotek Inc | Antigen GM-CSF peptides and GM-CSF antibodies |
| SI2423230T1 (sl) | 2006-03-27 | 2013-09-30 | Medimmune Limited | Vezni ÄŤlen za receptor GM-CSF |
| MX2009005398A (es) | 2006-11-21 | 2009-08-20 | Kalobios Pharmaceuticals Inc | Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf. |
| US7951368B2 (en) | 2007-06-25 | 2011-05-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| DK2215119T3 (da) | 2007-11-13 | 2013-02-04 | Evec Inc | Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme. |
| MX2010011761A (es) | 2008-04-28 | 2010-11-30 | Kalobios Pharmaceuticals Inc | Anticuerpos para el factor que estimula la colonia del granulocito-macrofago. |
| WO2009133103A1 (en) | 2008-04-29 | 2009-11-05 | Micromet Ag | Inhibitors of gm-csf and il-17 for therapy |
| RU2630969C2 (ru) | 2008-12-22 | 2017-09-15 | Де Юниверсити Оф Мельбурн | Лечение боли |
| JP2012530047A (ja) | 2009-05-05 | 2012-11-29 | モルフォシス・アー・ゲー | 多発性硬化症のための治療 |
| EP2458990B1 (en) | 2009-07-28 | 2016-03-30 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| EP2519262A2 (en) | 2009-12-29 | 2012-11-07 | F. Hoffmann-La Roche AG | Antibody formulation |
| RU2012139181A (ru) | 2010-02-26 | 2014-04-10 | Ново Нордиск А/С | Стабильная композиция, содержащая антитело |
| EP2399604A1 (en) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| JP6239517B2 (ja) * | 2011-10-10 | 2017-11-29 | メディミューン リミテッド | 関節リウマチの治療法 |
| PE20151079A1 (es) | 2012-09-20 | 2015-08-07 | Morphosys Ag | Tratamiento para artritis reumatoide |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res (Munich) Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| WO2014068029A1 (en) * | 2012-10-31 | 2014-05-08 | Takeda Gmbh | Lyophilized formulation comprising gm-csf neutralizing compound |
| JP6346389B1 (ja) | 2016-08-03 | 2018-06-20 | 古河電気工業株式会社 | 金属粒子含有組成物 |
-
2014
- 2014-09-01 BR BR112016003293A patent/BR112016003293A8/pt not_active Application Discontinuation
- 2014-09-01 KR KR1020227010431A patent/KR20220045064A/ko not_active IP Right Cessation
- 2014-09-01 CN CN202410511905.9A patent/CN118178647A/zh active Pending
- 2014-09-01 AU AU2014314053A patent/AU2014314053C1/en active Active
- 2014-09-01 KR KR1020247017478A patent/KR20240090993A/ko active Search and Examination
- 2014-09-01 RU RU2016109944A patent/RU2714919C2/ru active
- 2014-09-01 US US14/913,578 patent/US10745475B2/en active Active
- 2014-09-01 ES ES14758384T patent/ES2860480T3/es active Active
- 2014-09-01 EP EP14758384.3A patent/EP3039039B1/en active Active
- 2014-09-01 CN CN201480047403.XA patent/CN105705518A/zh active Pending
- 2014-09-01 EP EP21161450.8A patent/EP3889178A1/en active Pending
- 2014-09-01 CA CA2922251A patent/CA2922251C/en active Active
- 2014-09-01 KR KR1020167007575A patent/KR20160044035A/ko not_active IP Right Cessation
- 2014-09-01 MX MX2016002177A patent/MX2016002177A/es unknown
- 2014-09-01 WO PCT/EP2014/068489 patent/WO2015028657A1/en active Application Filing
- 2014-09-01 JP JP2016537322A patent/JP2016536327A/ja active Pending
-
2016
- 2016-02-18 MX MX2021010472A patent/MX2021010472A/es unknown
-
2020
- 2020-03-11 JP JP2020042267A patent/JP2020109108A/ja active Pending
- 2020-06-12 AU AU2020203917A patent/AU2020203917A1/en not_active Abandoned
- 2020-08-17 US US16/995,617 patent/US11795216B2/en active Active
-
2022
- 2022-05-02 JP JP2022076303A patent/JP2022105160A/ja active Pending
-
2023
- 2023-08-04 AU AU2023210647A patent/AU2023210647A1/en active Pending
-
2024
- 2024-06-27 JP JP2024103720A patent/JP2024123249A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023210647A1 (en) | 2023-10-12 |
| BR112016003293A2 (pt) | 2017-11-21 |
| US20210171620A1 (en) | 2021-06-10 |
| JP2022105160A (ja) | 2022-07-12 |
| US11795216B2 (en) | 2023-10-24 |
| CN118178647A (zh) | 2024-06-14 |
| EP3039039B1 (en) | 2021-03-10 |
| RU2714919C2 (ru) | 2020-02-21 |
| US10745475B2 (en) | 2020-08-18 |
| RU2016109944A (ru) | 2017-10-06 |
| ES2860480T3 (es) | 2021-10-05 |
| WO2015028657A1 (en) | 2015-03-05 |
| CN105705518A (zh) | 2016-06-22 |
| AU2020203917A1 (en) | 2020-07-02 |
| JP2024123249A (ja) | 2024-09-10 |
| US20160355584A1 (en) | 2016-12-08 |
| AU2014314053C1 (en) | 2023-11-02 |
| RU2016109944A3 (pt) | 2018-07-09 |
| MX2021010472A (es) | 2021-10-01 |
| KR20220045064A (ko) | 2022-04-12 |
| MX2016002177A (es) | 2016-06-28 |
| JP2020109108A (ja) | 2020-07-16 |
| AU2014314053A1 (en) | 2016-02-11 |
| CA2922251C (en) | 2023-10-17 |
| EP3039039A1 (en) | 2016-07-06 |
| KR20240090993A (ko) | 2024-06-21 |
| EP3889178A1 (en) | 2021-10-06 |
| JP2016536327A (ja) | 2016-11-24 |
| CA2922251A1 (en) | 2015-03-05 |
| AU2014314053B2 (en) | 2020-03-12 |
| KR20160044035A (ko) | 2016-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016003293A8 (pt) | Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos | |
| BR112015015891A8 (pt) | Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica | |
| BR112017000664A2 (pt) | anticorpo anti-pd-1 e seu uso | |
| BR112019017329A2 (pt) | imunoconjugados, um ou mais polinucleotídeos e vetores, métodos para a produção de um imunoconjugado, tratamento de uma doença e para a estimulação do sistema imunológico, composição, uso do imunoconjugado, invenção e usos da composição | |
| BR112019004764A2 (pt) | inibidores bicíclicos fundidos da interação menina-mll | |
| BR112018014615A2 (pt) | composições de anticorpo para ror1 e métodos relacionados | |
| BR112014008764A8 (pt) | Usos de um anticorpo, anticorpo, composição farmacêutica e combinação para o tratamento de artrite reumatoide | |
| BR112018011781A2 (pt) | molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica | |
| BR112019012354A2 (pt) | anticorpos apenas de cadeia pesada anti-bcma | |
| BR112015021134A2 (pt) | conjugados de fármaco e anticorpo | |
| UA118441C2 (uk) | Антитіло, що розпізнає альфа-синуклеїн | |
| EA201690633A1 (ru) | Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела | |
| BR112015029395A2 (pt) | Anticorpos anti-b7-h5 e seus usos | |
| BR112015015870A8 (pt) | composição farmacêutica, e, uso de uma composição farmacêutica | |
| BR112015022597A2 (pt) | partículas modificadoras da imunidade para o tratamento de inflamação | |
| BR112013021863A2 (pt) | anticorpos anti-receptor il-6 e métodos de uso | |
| EA201890320A1 (ru) | Молекулы антител, которые связывают cd79 | |
| BR112015021979A2 (pt) | Anticorpos humanos para grem1 | |
| BR112019005328A2 (pt) | composição farmacêutica líquida | |
| CO2017009433A2 (es) | Proteínas específicas para pioverdina y pioquelina | |
| EA201592203A1 (ru) | Способы лечения таупатии | |
| BR112015023262B8 (pt) | Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo | |
| BR112012005957A2 (pt) | compostos tricíclicos e usos farmacêuticos dos mesmos | |
| BR112016019176A2 (pt) | anticorpos il-21 | |
| EA201690159A1 (ru) | Способы и композиции для лечения рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |